title: Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.
abstract: Acute promyelocytic leukemia (APL) is efficiently treated with a cell differentiation inducer, all-trans retinoic acid (ATRA). However, a significant percentage of patients still develop resistance to this treatment. Recently, arsenic trioxide (As2O3), alone or in combination with ATRA, has been identified as an alternative therapy in patients with both ATRA-sensitive and ATRA-resistant APL. Previous investigations restricted the mechanism of this synergism to the modulation and/or degradation of PML-RARalpha oncoprotein through distinct pathways. In this study, using several ATRA maturation-resistant APL cell lines, we demonstrate in vitro that the success of ATRA/As2O3 treatment in APL pathology can be explained, at least in part, by a synergistic effect of these two drugs in triggering downregulation of telomerase efficient enough to cause telomere shortening and subsequent cell death. Such long-term low-dose combinatorial therapy strategies, developed also to avoid acute side effects, reinforce the notion that the antitelomerase strategy, based on a combination of active agents, should now be considered and evaluated not only in APL but also in other malignancies.
authors.affiliation: INSERM U685, Hôpital Saint-Louis, Institut d'Hématologie, Paris, France.
authors.forename: I
authors.initials: I
authors.lastname: Tarkanyi
authors.forename: C
authors.initials: C
authors.lastname: Dudognon
authors.forename: J
authors.initials: J
authors.lastname: Hillion
authors.forename: F
authors.initials: F
authors.lastname: Pendino
authors.forename: M
authors.initials: M
authors.lastname: Lanotte
authors.forename: J
authors.initials: J
authors.lastname: Aradi
authors.forename: E
authors.initials: E
authors.lastname: Ségal-Bendirdjian
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D004268:DNA-Binding Proteins / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D009363:Neoplasm Proteins / Q000378:metabolism; D015514:Oncogene Proteins, Fusion / Q000378:metabolism; D010087:Oxides / Q000008:administration & dosage; D012074:Remission Induction; D019098:Telomerase / Q000378:metabolism*; D016615:Telomere / Q000378:metabolism; D014212:Tretinoin / Q000008:administration & dosage; D014407:Tumor Cells, Cultured
chemical_list: D001152:Arsenicals; D004268:DNA-Binding Proteins; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D010087:Oxides; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin; D019098:Telomerase; D000077237:Arsenic Trioxide